Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
102.60    0.80 (0.79%)
Bid:
103.00
Ask:
103.80
Spread: 0.80 (0.777%)
Market Cap: £168.21m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Trading statement - Autumn 2025

23 Oct 2025 07:00

RNS Number : 4657E
Synthomer PLC
23 October 2025
 

Synthomer plcAutumn 2025 trading statement

Resilient performance in soft end-market environment

 

Synthomer plc ('Synthomer' or the 'Group') today issues a scheduled update on trading for the third quarter of 2025.

 

· Resilient Q3 2025 performance against a continuing soft market backdrop, led by Adhesive Solutions

· Additional self-help actions delivering an increasing benefit through the second half, mitigating subdued end-market conditions following trade tensions

· Expect Continuing EBITDA for 2025 to be similar to 2024

· Continued focus on strategic transformation and broadened divestment programme

 

Q3 2025 saw a continuation of soft demand across a number of end markets, which the Group was largely able to mitigate through our additional self-help initiatives. The Adhesive Solutions division continued to regain share and enhance margins, supported by our investment in increased APO capacity for adhesive applications at our Texas facility, which came onstream in July. Health & Protection volumes for the medical glove market remained subdued in the period, although our customers are increasingly confident of benefiting from their improved competitiveness in the US medical glove market following tariff changes. End markets in the Coatings & Construction Solutions division were more varied in the period - improving construction and relatively stable consumer sub-segments were offset by a slowdown in coatings demand particularly in the USA and low levels of oil and gas drilling activity affecting the energy solutions business. As anticipated, our 'in region, for region' manufacturing strategy means we are experiencing limited direct tariff impact which we are largely offsetting through surcharges, but we remain mindful that ongoing uncertainties around the global trade environment continue to create volatility in end-market demand.

 

As previously described, the Group has responded to the market environment by identifying additional rationalisation and cost efficiency opportunities. The new programme announced in August, which includes the removal of around 250 roles globally from the organisation, has now largely been completed and is on track to deliver c.£20-25m in savings on an annual run-rate basis by 2026. This programme supplements the previously identified benefits from robust pricing and the efficiency, reliability improvement and other 'self-help' actions implemented in 2025.

 

Alongside operational execution, we continue to focus on the strategic transformation of the Group and on strengthening our balance sheet. Having divested William Blythe in May, we continue to progress the Group's broadened divestment pipeline in order to accelerate the Group's deleveraging and simplify the portfolio further. Focus on cash generation is helping to ensure that the Group retains ample committed liquidity (after repayment of the stub 2025 bonds on 2 July 2025).

 

With our additional self-help actions largely mitigating the soft end-market demand conditions that we anticipate will persist for the remainder of 2025, we expect Continuing Group EBITDA for the year to be similar to the £143m reported in 2024, and expect a cash inflow in H2 to result in broadly neutral Free Cash Flow for the year. As we begin to look to 2026, we anticipate progress in Group earnings and cash generation as a result of full year contributions from our self-help actions and product investments.

 

Commenting, Synthomer CEO Michael Willome said:

"With ongoing global geopolitical and tariff-related turbulence continuing to unbalance demand and supply in our end markets, we have sharpened our focus on what we can control - expanding our cost saving programme, accelerating the transformation of our business portfolio and allocating resources even more rigorously to strengthen our financial position. We have clear commercial, operational and strategic plans in place, which are contributing to greater resilience and a stronger portfolio mix with considerable operating leverage to end-market demand recovery. As such, we remain confident in our objective to double Synthomer's recent earnings levels in the medium term, through our cost actions and strategy of focusing the business on market-leading speciality products with sustainable, differentiated benefits for global end-users."

 

Further information:

Investors: Faisal Tabbah, Vice President Investor Relations

Tel: +44 (0) 1279 775 306

Media: Nick Hasell, FTI Consulting

Tel: +44 (0) 203 727 1340

 

Notes

Synthomer plc is a leading supplier of high-performance, highly specialised polymers and ingredients that play vital roles in key sectors such as coatings, construction, adhesives, and health and protection - growing markets for customers who serve billions of end users worldwide. Headquartered in London, UK and listed there since 1971, we employ c.3,900 employees across our five innovation centres of excellence and 29 manufacturing sites across Europe, North America, Middle East and Asia. With more than 6,000 blue-chip customers and £2.0bn in continuing revenue in 2024, our business is built around three divisions, serving customers in attractive end markets where demand is driven by global megatrends including urbanisation, demographic change, climate change and sustainability, and shifting economic power.

 

In Coatings & Construction Solutions, our specialist polymers enhance the sustainability and performance of a wide range of coatings and construction products. We serve customers in applications including architectural and masonry coatings, mortar modification, waterproofing and flooring, fibre bonding, and energy solutions. In Adhesive Solutions our products help our customers bond, modify and compatibilise surfaces and components for applications including tapes and labels, packaging, hygiene, tyres and plastic modification, improving permeability, strength, elasticity, damping, dispersion and grip. In Health & Protection and Performance Materials we are a world-leading supplier of water-based polymers for medical gloves, and a major European manufacturer of high-performance binders, foams and other products serving customers in a range of end markets.

 

Our purpose is creating innovative and sustainable solutions for the benefit of customers and society. Around 20% of our sales volumes are from new and patent protected products. At our innovation centres of excellence in the UK, China, Germany, Malaysia and Ohio, USA we collaborate closely with our customers to develop new products and enhance existing ones tailored to their needs, with an increasing range of sustainability benefits. Our 2030 decarbonisation targets have been approved by the Science Based Targets initiative as being in line with what the latest climate science says is necessary to meet the goals of the Paris Agreement, and since 2021 we have held the London Stock Exchange Green Economy Mark, which recognises green technology businesses making a significant contribution to a more sustainable, low-carbon economy. Find us at www.synthomer.com or search for Synthomer on LinkedIn.

 

Legal Entity Identifier (LEI): 213800EHT3TI1KPQQJ56. Classification as per DTR 6 Annex 1R: 3.1.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFFDIVLFFIE
Date   Source Headline
17th May 20077:01 amRNSAGM Statement
15th May 20074:29 pmRNSAnnual Report and Accounts
20th Apr 20079:40 amRNSAnnual Information Update
19th Apr 200712:47 pmRNSHolding(s) in Company
10th Apr 20075:26 pmRNSDirectorate Change
29th Mar 20074:37 pmRNSHolding(s) in Company
22nd Mar 200712:30 pmRNSDirectorate Change
12th Mar 20071:05 pmRNSDirector/PDMR Shareholding
12th Mar 20071:00 pmRNSDirector/PDMR Shareholding
7th Mar 20077:01 amRNSFinal Results
6th Mar 20074:04 pmRNSHolding(s) in Company
20th Feb 20074:29 pmRNSNotice of Results
1st Feb 20074:23 pmRNSBlocklisting Interim Review
18th Dec 20062:08 pmRNSVoting Rights and Capital
15th Dec 20067:58 amRNSTrading Statement
4th Dec 200612:49 pmRNSBlocklisting Interim Review
12th Oct 200610:46 amRNSHolding(s) in Company
2nd Oct 20063:20 pmRNSDirector/PDMR Shareholding
8th Sep 20069:01 amRNSDirector/PDMR Shareholding
7th Sep 20067:01 amRNSInterim Results
21st Aug 20063:22 pmRNSNotice of Results
21st Aug 20062:41 pmRNSDirectorate Change
1st Aug 20062:51 pmRNSBlocklisting Interim Review
14th Jul 20063:51 pmRNSNew Chief Executive
7th Jun 200611:14 amRNSDirector/PDMR Shareholding
5th Jun 20067:00 amRNSDisposal of Reabrook Limited
1st Jun 20064:48 pmRNSBlocklisting Interim Review
25th May 20063:11 pmRNSDirector/PDMR Shareholding
25th May 20063:09 pmRNSDirector/PDMR Shareholding
18th May 20064:59 pmRNSResult of AGM
18th May 200612:00 pmRNSAGM Statement
3rd May 200612:28 pmRNSAnnual Information Update
18th Apr 20063:49 pmRNSAnnual Report and Accounts
13th Apr 200611:30 amRNSDirector/PDMR Shareholding
13th Apr 200611:28 amRNSDirector/PDMR Shareholding
21st Mar 200612:05 pmRNSDirector/PDMR Shareholding
16th Mar 20067:01 amRNSFinal Results
20th Feb 20063:44 pmRNSHolding(s) in Company
20th Feb 20062:00 pmRNSAppointment
9th Feb 200612:10 pmRNSNotice of Results
31st Jan 200610:00 amRNSAdditional Listing
30th Dec 200512:00 pmRNSWithdrawal from SO2 business
23rd Dec 200510:14 amRNSDirector/PDMR Shareholding
14th Dec 20057:00 amRNSPre-close Trading Statement
8th Dec 20051:29 pmRNSBlocklisting Interim Review
7th Dec 20058:42 amRNSSale of Autoclenz Limited
7th Dec 20057:01 amRNSAdmission to trading on AIM
6th Dec 20054:23 pmRNSDirector Declaration
6th Dec 20054:18 pmRNSDirectorate Change
2nd Dec 200510:07 amRNSSale of Autoclenz Limited

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.